How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance

Leukemia. 2008 Dec;22(12):2257-8. doi: 10.1038/leu.2008.114. Epub 2008 May 15.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Fatal Outcome
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Male
  • Middle Aged
  • Rituximab
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Tumor Suppressor Protein p53
  • Rituximab